Abstract
Introduction: The most serious COVID-19 deriving from severe acute respiratory syndrome coronavirus 2 causes a cytokine release storm and it is associated with worse outcomes. In COVID-19 patients, interleukin-6 (IL-6) levels are significantly elevated. Blocking IL-6 preliminarily resulted in the improvement of this hyperinflammatory state. It is unknown which patients could require higher doses of tocilizumab to get out of the cytokine storm.
Materials and methods: Twenty-four patients affected by COVID-19 pneumonia were included. All the patients underwent tocilizumab 8 mg/kg intravenously and were tested for serum IL-6 24 to 48 hours before and 12 to 48 hours after tocilizumab infusion. Comparisons between survivors and nonsurvivors were performed.
Results: Eighteen patients were discharged, while six patients died, with no clinical or laboratory differences between the two groups at baseline. IL-6 was not different at baseline (P = .41), while 24 to 48 hours post-tocilizumab IL-6 serum levels were significantly higher in nonsurvivors than in survivors (2398.5 [430.5-9372] vs 290.5 [58.5-1305.5] pg/mL, P = .022). Serum IL-6 post-tocilizumab showed a good predictive ability to discriminate survivors from nonsurvivors (area under the curve, 0.815; 95% confidence interval, 0.63-0.99, P = .02).
Conclusion: Repeated measurement of the serum level of IL-6 early after tocilizumab may distinguish nonsurvivors from survivors and support the choice of deeper targeting IL-6 in COVID-19 pneumonia.
Keywords: COVID-19; coronavirus; cytokine; interleukin-6; tocilizumab.
【저자키워드】 COVID-19, coronavirus, Tocilizumab, interleukin-6, cytokine, 【초록키워드】 Cytokine storm, coronavirus, COVID-19 pneumonia, Tocilizumab, Pneumonia, IL-6, interleukin-6, cytokine, severe acute respiratory syndrome Coronavirus, Laboratory, outcomes, serum, interleukin, Patient, respiratory, COVID-19 patients, cytokine release storm, hyperinflammatory state, dose, Predictive, 48 hours, get out, Support, Serum IL-6, acute respiratory syndrome, two groups, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, Serum level, 95% confidence interval, serum levels, nonsurvivors, choice, Comparisons, serious COVID-19, material, all the patients, intravenously, survivor, blocking, tested, performed, affected, significantly, elevated, significantly higher, cause, two group, not different, discharged, 48 hour, All the patient, baseline, nonsurvivor, patients died, the cytokine storm, 【제목키워드】 Tocilizumab, survivor, nonsurvivor,